Antengene Corporation Ltd
HKEX:6996
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antengene Corporation Ltd
Other Long-Term Assets
Antengene Corporation Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Other Long-Term Assets
¥22.5m
|
CAGR 3-Years
88%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Long-Term Assets
¥993.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
31%
|
CAGR 10-Years
29%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Long-Term Assets
¥1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Other Long-Term Assets
¥1.1B
|
CAGR 3-Years
47%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Long-Term Assets
¥229m
|
CAGR 3-Years
37%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Other Long-Term Assets?
Other Long-Term Assets
22.5m
CNY
Based on the financial report for Dec 31, 2025, Antengene Corporation Ltd's Other Long-Term Assets amounts to 22.5m CNY.
What is Antengene Corporation Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
88%
Over the last year, the Other Long-Term Assets growth was 877%. The average annual Other Long-Term Assets growth rates for Antengene Corporation Ltd have been 88% over the past three years .
